vs

Side-by-side financial comparison of Hippo Holdings Inc. (HIPO) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

Organogenesis Holdings Inc. is the larger business by last-quarter revenue ($225.6M vs $120.4M, roughly 1.9× Hippo Holdings Inc.). Organogenesis Holdings Inc. runs the higher net margin — 19.4% vs 5.0%, a 14.4% gap on every dollar of revenue. On growth, Organogenesis Holdings Inc. posted the faster year-over-year revenue change (78.1% vs 18.2%). Organogenesis Holdings Inc. produced more free cash flow last quarter ($34.8M vs $9.1M). Over the past eight quarters, Organogenesis Holdings Inc.'s revenue compounded faster (43.2% CAGR vs 18.9%).

Hippo Valley Estate is a sugar estate found near the town of Chiredzi in Chiredzi District of southeastern Zimbabwe, on the Runde River near the border with Mozambique.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

HIPO vs ORGO — Head-to-Head

Bigger by revenue
ORGO
ORGO
1.9× larger
ORGO
$225.6M
$120.4M
HIPO
Growing faster (revenue YoY)
ORGO
ORGO
+60.0% gap
ORGO
78.1%
18.2%
HIPO
Higher net margin
ORGO
ORGO
14.4% more per $
ORGO
19.4%
5.0%
HIPO
More free cash flow
ORGO
ORGO
$25.7M more FCF
ORGO
$34.8M
$9.1M
HIPO
Faster 2-yr revenue CAGR
ORGO
ORGO
Annualised
ORGO
43.2%
18.9%
HIPO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
HIPO
HIPO
ORGO
ORGO
Revenue
$120.4M
$225.6M
Net Profit
$6.0M
$43.7M
Gross Margin
Operating Margin
5.6%
28.1%
Net Margin
5.0%
19.4%
Revenue YoY
18.2%
78.1%
Net Profit YoY
-86.4%
469.5%
EPS (diluted)
$0.31
$0.31

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
HIPO
HIPO
ORGO
ORGO
Q4 25
$120.4M
$225.6M
Q3 25
$120.6M
$150.9M
Q2 25
$117.3M
$101.0M
Q1 25
$110.3M
$86.7M
Q4 24
$101.9M
$126.7M
Q3 24
$95.5M
$115.2M
Q2 24
$89.6M
$130.2M
Q1 24
$85.1M
$110.0M
Net Profit
HIPO
HIPO
ORGO
ORGO
Q4 25
$6.0M
$43.7M
Q3 25
$98.1M
$21.6M
Q2 25
$1.3M
$-9.4M
Q1 25
$-47.7M
$-18.8M
Q4 24
$44.2M
$7.7M
Q3 24
$-8.5M
$12.3M
Q2 24
$-40.5M
$-17.0M
Q1 24
$-35.7M
$-2.1M
Gross Margin
HIPO
HIPO
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Q1 24
73.9%
Operating Margin
HIPO
HIPO
ORGO
ORGO
Q4 25
5.6%
28.1%
Q3 25
81.3%
13.7%
Q2 25
3.4%
-12.5%
Q1 25
-41.3%
-30.9%
Q4 24
46.3%
8.1%
Q3 24
-5.4%
5.4%
Q2 24
-40.7%
-10.7%
Q1 24
-38.7%
-3.5%
Net Margin
HIPO
HIPO
ORGO
ORGO
Q4 25
5.0%
19.4%
Q3 25
81.3%
14.3%
Q2 25
1.1%
-9.3%
Q1 25
-43.2%
-21.7%
Q4 24
43.4%
6.1%
Q3 24
-8.9%
10.7%
Q2 24
-45.2%
-13.1%
Q1 24
-42.0%
-1.9%
EPS (diluted)
HIPO
HIPO
ORGO
ORGO
Q4 25
$0.31
$0.31
Q3 25
$3.77
$0.11
Q2 25
$0.05
$-0.10
Q1 25
$-1.91
$-0.17
Q4 24
$1.81
$0.05
Q3 24
$-0.34
$0.09
Q2 24
$-1.64
$-0.13
Q1 24
$-1.47
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
HIPO
HIPO
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$218.3M
$93.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$436.1M
$300.1M
Total Assets
$1.9B
$598.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
HIPO
HIPO
ORGO
ORGO
Q4 25
$218.3M
$93.7M
Q3 25
$247.7M
$63.7M
Q2 25
$198.9M
$73.1M
Q1 25
$140.9M
$110.0M
Q4 24
$197.6M
$135.6M
Q3 24
$191.2M
$94.3M
Q2 24
$175.9M
$89.9M
Q1 24
$223.4M
$88.6M
Total Debt
HIPO
HIPO
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
$62.3M
Q2 24
$63.8M
Q1 24
$65.2M
Stockholders' Equity
HIPO
HIPO
ORGO
ORGO
Q4 25
$436.1M
$300.1M
Q3 25
$421.5M
$255.1M
Q2 25
$332.5M
$233.2M
Q1 25
$322.8M
$242.9M
Q4 24
$362.1M
$262.9M
Q3 24
$326.4M
$278.5M
Q2 24
$322.6M
$263.5M
Q1 24
$351.2M
$278.0M
Total Assets
HIPO
HIPO
ORGO
ORGO
Q4 25
$1.9B
$598.7M
Q3 25
$1.9B
$509.8M
Q2 25
$1.7B
$461.1M
Q1 25
$1.5B
$467.4M
Q4 24
$1.5B
$497.9M
Q3 24
$1.5B
$446.3M
Q2 24
$1.5B
$443.2M
Q1 24
$1.5B
$458.5M
Debt / Equity
HIPO
HIPO
ORGO
ORGO
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
0.22×
Q2 24
0.24×
Q1 24
0.23×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
HIPO
HIPO
ORGO
ORGO
Operating Cash FlowLast quarter
$9.2M
$39.4M
Free Cash FlowOCF − Capex
$9.1M
$34.8M
FCF MarginFCF / Revenue
7.6%
15.4%
Capex IntensityCapex / Revenue
0.1%
2.1%
Cash ConversionOCF / Net Profit
1.53×
0.90×
TTM Free Cash FlowTrailing 4 quarters
$14.8M
$-24.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
HIPO
HIPO
ORGO
ORGO
Q4 25
$9.2M
$39.4M
Q3 25
$16.9M
$3.1M
Q2 25
$24.7M
$-32.9M
Q1 25
$-35.6M
$-19.9M
Q4 24
$47.5M
$10.9M
Q3 24
$46.8M
$8.7M
Q2 24
$-10.6M
$4.7M
Q1 24
$17.7M
$-10.2M
Free Cash Flow
HIPO
HIPO
ORGO
ORGO
Q4 25
$9.1M
$34.8M
Q3 25
$16.8M
$844.0K
Q2 25
$24.6M
$-36.5M
Q1 25
$-35.7M
$-23.6M
Q4 24
$47.2M
$7.6M
Q3 24
$6.1M
Q2 24
$-10.7M
$2.9M
Q1 24
$17.6M
$-12.4M
FCF Margin
HIPO
HIPO
ORGO
ORGO
Q4 25
7.6%
15.4%
Q3 25
13.9%
0.6%
Q2 25
21.0%
-36.1%
Q1 25
-32.4%
-27.2%
Q4 24
46.3%
6.0%
Q3 24
5.3%
Q2 24
-11.9%
2.2%
Q1 24
20.7%
-11.3%
Capex Intensity
HIPO
HIPO
ORGO
ORGO
Q4 25
0.1%
2.1%
Q3 25
0.1%
1.5%
Q2 25
0.1%
3.6%
Q1 25
0.1%
4.2%
Q4 24
0.3%
2.7%
Q3 24
0.0%
2.2%
Q2 24
0.1%
1.4%
Q1 24
0.1%
2.0%
Cash Conversion
HIPO
HIPO
ORGO
ORGO
Q4 25
1.53×
0.90×
Q3 25
0.17×
0.14×
Q2 25
19.00×
Q1 25
Q4 24
1.07×
1.43×
Q3 24
0.71×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons